Stock Financial Ratios, Dividends, Split History

NBEV / New Age Beverages Corporation financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)67.05
Enterprise Value ($M)66.95
Book Value ($M)50.50
Book Value / Share1.29
Price / Book1.53
NCAV ($M)-0.34
NCAV / Share-0.01
Price / NCAV-218.69
Share Statistics
Common Stock Shares Outstanding 35,171,419
Common Shares Outstanding 38,933,646
Weighted Average Number Of Shares Outstanding Basic 30,616,506
Weighted Average Number Of Diluted Shares Outstanding 60,616,506
Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma 34,330,520
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.07
Return on Assets (ROA)-0.13
Return on Equity (ROE)-0.72
Balance Sheet (mrq) ($M)
Quick Ratio0.74
Current Ratio1.37
Income Statement (mra) ($M)
Advertising Revenue0.00
Disposal Group Including Discontinued Operation Revenue56,144,428.00
Sales Revenue Net52,188,295.00
Operating Income-6.05
Net Income-3.54
Earnings Per Share Basic And Diluted-0.12
Cash Flow Statement (mra) ($M)
Cash From Operations-8.41
Cash from Investing6.23
Cash from Financing6.23
Identifiers and Descriptors
Central Index Key (CIK)1579823
Industry Groups
SIC 2082 - Malt Beverages

Split History

Stock splits are used by New Age Beverages Corporation to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
NBEV: New Age Beverages Corporation Analysis and Research Report

2018-03-01 - Asif

New Age Beverages is a leading organic and natural healthy functional beverage company engaged in the development, marketing, sales and distribution of a portfolio of Ready-to-Drink (RTD) better-for-you beverages. The company has competitive entrants in the top 5 fastest growing segments of the beverage industry and competes in the RTD Tea, RTD Coffee, Coconut Water, Kombucha, Functional Waters, Rehydration Beverages, Carbonated Beverages and Energy drink segments. The company differentiate its brands through functional characteristics and ingredients and offer only organic and natural better-for-you products, with no HFCS, no GMOs, no preservatives, and only natural flavors, fruits, and other ingredients. The company manufacture its products in its own fully-integrated manufacturing facilities and through a network of ten additional manufacturers strategically located throughout the United States. The company's products are currently distributed in 10 countries internationally, and in...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Pass On New Age Beverages

2018-05-22 seekingalpha
Reasons for skepticism include a poor track record, bad incentives for management, questionable health benefits of products, and weak profitability. (6-2)

New Age Beverages' (NBEV) CEO Brent Willis on Q1 2018 Results - Earnings Call Transcript

2018-05-17 seekingalpha
New Age Beverages Corporation (NASDAQ:NBEV) Q1 2018 Earnings Conference Call May 15, 2018 5:00 PM ET (6-0)

New Age Beverages' (NBEV) CEO Brent Willis on Q4 2017 Results - Earnings Call Transcript

2018-04-17 seekingalpha
New Age Beverages Corporation (NASDAQ:NBEV) Q4 2017 Earnings Conference Call April 17, 2018 5:00 PM ET (6-2)

BRIEF-New Age Beverages Terminates At Market Issuance Sales Agreement Dated March 23, Between Co & B. Riley FBR

2018-04-13 reuters

CUSIP: 64157V108